Skip to main content

Table 2 Distribution of first episode of leprosy reactions and main clinical manifestations developed by patients stratified by R&J groups

From: Can baseline ML Flow test results predict leprosy reactions? An investigation in a cohort of patients enrolled in the uniform multidrug therapy clinical trial for leprosy patients in Brazil

 

I

TT

BT

BB

BL

LL

TOTAL (%)

Reactions

0

6

105

31

190

86

418 (55.5)

 RR

0

2

28

16

92

0

138 (18.3)

 ENL

0

0

0

0

13

28

41 (5.4)

 Necrotising ENL

0

0

0

0

0

1

1 (0.1)

 Lymphadenopathy

0

0

0

0

1

1

2 (0.2)

 Reaction hand and foot

0

0

4

1

8

6

19 (2.5)

 ENL + Polymorphic Erythema

0

0

0

0

1

0

1 (0.1)

 ENL + Orchitis

0

0

0

0

0

1

1 (0.1)

 ENL + Arthritis

0

0

0

0

0

1

1 (0.1)

 ENL + Lymphadenopathy

0

0

0

0

1

1

2 (0.3)

 ENL + reactional hand and foot

0

0

0

0

0

3

3 (0.4)

 Mixed reaction / Type 1 + Type 2

0

0

0

1

6

1

8 (1.1)

 Neuritis

0

3

59

8

43

36

149 (19.8)

 Neuritis + RR

0

1

9

4

14

0

28 (3.7)

 Neuritis + ENL

0

0

0

0

2

5

7 (0.9)

 Neuritis + Mixed reaction

0

0

0

0

1

0

1 (0.1)

 Neuritis + Arthritis

0

0

1

0

1

0

2 (0.3)

 Neuritis + Orchitis

0

0

1

0

0

0

1 (0.1)

 Neuritis + reactional hand and foot

0

0

3

1

7

1

12 (1.6)

 Neuritis + ENL + polymorphic erythema

0

0

0

0

0

1

1 (0.1)

Reaction-free

11

42

190

10

44

38

335 (44.5)

Total

11

48

295

41

234

124

753 (100)